Related video above: Moderna working to have COVID-19 vaccines for children as young as 5 by early fallModerna has released its latest findings from a third-phase study of patients receiving its COVID-19 vaccine.According to a release from the company, the data shows 93% efficacy six months after the second dose. 바카라 게임 웹사이트�We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the delta variant is a significant new threat so we must remain vigilant,바카라 게임 웹사이트� CEO Stephane Bancel said. The Massachusetts-based company also said a study in its second phase "induced robust antibody responses" against the gamma, beta and delta variants of COVID-19 for three booster candidates. The company has submitted this data to a peer-reviewed journal for publication. The company said it believes a booster will be necessary before winter."We believe a booster (dose 3) is likely to be necessary this fall, particularly in the face of Delta," the company said. The company also has ongoing efficacy studies for adolescent and pediatric patients.Moderna also noted it was looking forward to developing a single-dose annual booster that provides protection against COVID-19, flu and RSV in adults.